Metastatik Meme Kanseri
Özet
Meme kanseri tedavisi sonrasında yapılan izlemin amaçları; ikinci bir primer gelişip gelişmediğini gözlemlemek, tedavi ile ilgili komplikasyonları belirlemek ve tedavi etmek, tedaviye uyumu ve psikososyal desteği sağlamak, hastalıkla ilgili nüks gelişip gelişmediğini tespit etmek ve lokal nüks geliştiğinde müdahale etmek olarak sıralanabilir. Meme kanseri, primer tedaviden sonra rutin olarak takip edilmektedir. Birçok tanı yöntemi (tümör belirteçleri, akciğer grafisi, mamografi, kemik taramaları gibi) periyodik olarak yapılmaktadır. Yapılan randomize çalışmalara dayanarak, düzenli göğüs veya abdominal görüntüleme, biyokimya panelleri veya tümör marker ölçümleri ile takip süreci bu tür hastalarda sağkalımı etkilemektedir. Sistemik tedavide son zamanlardaki önemli gelişmeler göz önüne alındığında; daha sıklıkta yapılan takip sürecinin modern çağda, tedavi sonuçlarını iyileştirebileceği düşünülmektedir.
The purposes of follow-up after breast cancer treatment are; It can be listed as observing whether a second primary develops, identifying and treating treatment-related complications, ensuring compliance with treatment and psychosocial support, determining whether disease-related recurrence develops, and intervening when local recurrence develops. Breast cancer is routinely followed after primary treatment. Many diagnostic methods (such as tumor markers, chest x-ray, mammography, bone scans) are performed periodically. Based on randomized studies, the follow-up process with regular breast or abdominal imaging, biochemistry panels, or tumor marker measurements affects survival in such patients. Considering the recent significant developments in systemic treatment; It is thought that the more frequent follow-up process can improve treatment outcomes in the modern age.
Referanslar
Siegel RL, M.,et al., Cancer statistics, CA Cancer J Clin. 2023 Jan; 73(1):p17-48. doi:10.3322/caac.21763.
Chia SK, Speers CH, D'yachkova Y,et al.The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973.
Dafni U, Grimani I, Xyrafas A,et al.Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2010;119(3):621.
Stockler M, Wilcken NR, Ghersi D, Simes R. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26(3):151
Montgomery DA, Krupa K, Cooke TG .Alternative methods of follow up in breast cancer: a systematic review of the literatür.Br J Cancer. 2007;96(11):1625.
Gao J.J, Cheng J.Bloomquist E, et al.CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.Lancet Oncol. 2020 ;21(2) :250-260
Cardosa F,Paluch-Shimon S, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).Ann Oncol.2020;31(12):1623-1649
Lee Cl,Gold LS,Nelson HD,et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response.Breast.2015;24(1):3-11.
Accordino MK, Wright JD, Vasan S, et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol. 2016;34(24):2820-2826.
Lee CI, Gold LS, Nelson HD, et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2015;24(1):3-11.
Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol. 2011;29(22):3072-3077
Komorowski AS, Warner E, MacKay HJ, et al. Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for ccreening? Clin Breast Cancer. 2020;20(1):e54-e64
Swenerton KD, Legha SS, Smith T,et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy.Cancer Res. 1979;39(5):1552.
Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al.Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987.
Ahmann DL, Schaid DJ, Bisel HF, Hahn RG,et al.The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol. 1987;5(12):1928
Robertson JF, Howell A, Buzdar A,et al.Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat. 1999;58(2):157.
Harris L, Fritsche H, Mennel R, Norton L,et al.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287.
Stearns V, Yamauchi H, Hayes DF.Circulating tumor markers in breast cancer: accepted utilities and novel prospects.Breast Cancer Res Treat. 1998;52(1-3):239.
Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D,et al.Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology. 2004;67(5-6):359.
Janicek MJ, Hayes DF, Kaplan WD .Healing flare in skeletal metastases from breast cancer. Radiology. 1994;192(1):201.
Stafford SE, Gralow JR, Schubert EK,et al.Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002;9(8):913.
Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ .Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003;88(7):1091.
Hayes DF, Cristofanilli M, Budd GT,et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218.
Budd GT, Cristofanilli M, Ellis MJ,et al.Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.Clin Cancer Res. 2006;12(21):6403.
Liu MC, Shields PG, Warren RD,et al.Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline [version 1.1]. Eur J Cancer 2009;45:228-247
Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 Suppl 1:1-1.
Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011;15:21-30.
Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010;15:1164-1168.
Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010;15:1164-1168
Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416-423.
Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776-782.
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open label randomised controlled trial. Lancet Oncol 2015;16:1380-1388.
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open label randomised controlled trial. Lancet Oncol 2015;16:1380-1388.
King TA, Lyman J, Gonen M, et al. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Journal of Clinical Oncology 2016;34:1006-1006
Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008;22:614-623.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-3489.
Gennari A, Conte P, Rosso R, Orlandini C, et al.Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742.
Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, et al.Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr. 2018;2(4):pky062. Epub 2018 Dec 24.
Ben-Haim S, İsrail O , et al.Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39(6):408.
R.C. Coombes, K. Page, R. Salari,et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence:Clin Cancer Res 2019;25:4255–63.
Suthinee İthimakin, Natthakit Luengwatthanakit, et al.Follow-Up Strategies and Detection of Recurrent Breast Cancer in the Modern Era;Asian Pac J Cancer Pre. 2023 Apr 1;24(4):1359-1366
Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goer- res GW. [18F]-Fluorodeoxyglucose positron emission to- mography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129(3):147-53.
Taghipour M, Sheikhbahaei S, Trahan TJ, et al. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nucl Med Commun. 2016;37:602–8. doi: 10.1097/MNM.0000000000000491
Thomas DB, Gao DL, Ray RM, et al: Randomized trial of breast self-examination in Shanghai: Final results. J Natl Cancer Inst 2002;94:1445-1457.
Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007;97(12):1632-41.
Ciatto S, Herd-smith A. The role of chest x-ray in the follow- up of primary breast cancer. Tumori. 1983;69:151-4.
